28 results
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
of interest, corruption or bribery, including, if applicable, the U.S. Foreign Corrupt Practices Act of 1977, as amended (“FCPA”), the UK Bribery Act 2010 … , as amended, any laws enacted to implement the Organisation of Economic Cooperation and Development Convention on Combating Bribery of Foreign
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
it is a bellwether program and one we watch closely.
The U.S. Foreign Corrupt Practice Act, the UK Bribery Act 2010 and Other Anti-corruption Laws
The U.S … .
Our operations are also subject to non-U.S. anti-corruption laws such as the UK Bribery Act 2010 (the “UK Bribery Act”). As with the FCPA
8-K
EX-1.1
AUTL
Autolus Therapeutics plc
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
of the Bribery Act 2010 of the United Kingdom, the Foreign Corrupt Practices Act of 1977, or any other applicable anti-bribery or anti-corruption law;
(hh
8-K
EX-10.1
AUTL
Autolus Therapeutics plc
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
or indirect unlawful payment; or (iii) violated or is in violation of any provision of the Bribery Act 2010 of the United Kingdom, the Foreign Corrupt … Practices Act of 1977, or any other applicable anti-bribery or anti-corruption law.
4.21. Office of Foreign Assets Control. Neither the Company nor any
6-K
EX-1.1
AUTL
Autolus Therapeutics plc
9 Dec 22
Autolus Announces Pricing of Public Offering
5:43pm
; or (iii) violated or is in violation of any provision of the Bribery Act 2010 of the United Kingdom, the Foreign Corrupt Practices Act of 1977 … , or any other applicable anti-bribery or anti-corruption law;
(hh) The operations of the Company and its subsidiaries are and have been conducted at all
6-K
EX-1
5ubl5 lcz8xtb2dwvye
1 Jul 22
Current report (foreign)
5:15pm
6-K
EX-99.1
bwauuho9t gxowdsx
8 Nov 21
Securities Purchase Agreement
5:28pm
6-K
EX-1
yuye5tkpaih0cmfv5h6b
30 Jun 21
Annual Report and Accounts
6:05am
6-K
EX-1.1
27nroqr3
11 Feb 21
Autolus Announces Proposed Public Offering in the United States
5:18pm
6-K
EX-1.1
cnv437mq5 fi76
18 Sep 20
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO
7:12am
6-K
EX-1
xl362
26 May 20
Current report (foreign)
4:31pm
6-K
EX-1.1
vfsqn
24 Jan 20
Autolus Announces Proposed Public Offering in the United States
4:06pm
F-1
EX-1.1
nagpr 394fnzij0f
8 Apr 19
Registration statement (foreign)
4:34pm
6-K
EX-1
m3v3 t1huplyke8i002
15 Mar 19
Annual Report and Accounts
5:26pm
20-F
id12er qk6nsl
23 Nov 18
Annual report (foreign)
12:00am
424B4
vwcbmm6iu6n3
22 Jun 18
Prospectus supplement with pricing info
4:02pm